Presenter: Aleksey Shchulkin – Ryazan State Medical University, Russian Federation
Presentation Type: Oral Presentation (In-Person)
Title: Ethylmethylhydroxypyridine succinate (Mexidol®): Mechanisms and clinical evidence in ischemic stroke
🔬 Presentation Highlights
∙ Therapeutic Focus: Exploration of Ethylmethylhydroxypyridine succinate (Mexidol®) as a neuroprotective treatment for ischemic stroke.
∙ Antioxidant Activity: The compound neutralizes superoxide radicals and enhances antioxidant enzyme activity including superoxide dismutase and glutathione peroxidase while activating the NRF2 transcription factor.
∙ Hypoxia Protection: Supports mitochondrial respiratory chain activity under low oxygen conditions and activates the succinate receptor (SUCNR1) while influencing the HIF-1α transcription factor, improving cellular resistance to hypoxia.
∙ Neuroprotective Effects: Experimental studies demonstrate reduction of neuroinflammation and apoptosis while promoting neuroplasticity, which is critical for brain recovery after stroke.
∙ Preclinical Evidence: Animal studies modeling acute focal cerebral stroke showed significant improvement in neurological symptoms and reduction in hemorrhagic lesion size in treated groups compared with placebo.
∙ Clinical Trial Results: A double-blind placebo-controlled MIR study involving 304 ischemic stroke patients demonstrated:
Significant reduction in disability using the mRS scale
Improved neurological function measured by NIHSS
Enhanced mobility via the Rivermead Index
Trends toward cognitive improvement assessed by the MoCA test
∙ Safety Profile: Adverse events were comparable between drug and placebo groups, confirming long-term safety and tolerability of sequential therapy.
∙ Clinical Impact: Findings highlight Mexidol® as a promising therapeutic strategy for improving neurological recovery and functional outcomes in ischemic stroke patients.
👨⚕️ About the Speaker
Dr. Aleksey Shchulkin is a Professor in the Department of Pharmacology and Head of the Pharmacokinetics Laboratory at Ryazan State Medical University, Russia.
∙ Expert in pharmacokinetics and neuroprotection
∙ Leading research in drug mechanisms and therapeutic interventions for neurological disorders
∙ Active contributor to experimental and clinical studies focused on stroke therapy and neuroprotective pharmacology
🔗 Join the Conference
Event: International Conference on Neurology and Neuroscience
📅 March 23–25, 2026
📍 Singapore & Online
🌐 Event Website: https://neurocareconference.com/
🧬 Submit Abstract: https://neurocareconference.com/abstract-submission
📝 Register: https://neurocareconference.com/register
Connect with global neurologists, neuroscientists, clinicians, and researchers to explore the latest innovations in brain science, stroke therapy, neurodegeneration, and neurological care.
#Neurology #Neuroscience #StrokeResearch #IschemicStroke #Neuroprotection #Pharmacology #BrainHealth #NeuroScienceConference #NeurologyConference #ClinicalResearch #MedicalInnovation #StrokeTreatment #Neuropharmacology #BrainResearch #HealthcareInnovation #SingaporeConference #NeuroCare2026
No comments:
Post a Comment